KRAS and pancreatic intraductal papillary-mucinous neoplasm: Another IPMN mouse model comprising the transgenic overexpression of Tgfα under the control of the pancreatic Elastase promoter (Ela-Tgfα), combined with the KRAS G12D mutation, is highly metastatic, with the rate of 50% at 6–8 months, predominantly in liver, lung, peritoneum, and lymph nodes [26].